Ruxolitinib
Especificaciones
941678-49-5Número CAS
107-728-9Número CE
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrileNombre IUPAC
C17H18N6Fórmula química
306.4 g/molPeso molecular
Ruxolitinib; 941678-49-5; INCB018424; INCB-018424; INCB18424; INC424; 82S8X8XX8H; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; INC-424; INCB-18424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; CHEBI:66919; DTXSID10240930; (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile; (3R)-3-CYCLOPENTYL-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PYRAZOL-1-YL)PROPANENITRILE; 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-; ruxolitinibum; (3R)-3-cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile; (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}pyrazol-1-yl)propanenitrile; RefChem:6207; INCA24; DTXCID40163421; L01XE18; Oral JAK Inhibitor INCB18424; 3R)-3-cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile; 107-728-9; Ruxolitinib (INCB018424); (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; INCB 018424; Jakavi; (R)-ruxolitinib; MFCD12031592; C17H18N6; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (Synonyms:Ruxolitinib); (R)-Ruxolitinib (>90%); R-Ruxolitinib; Ruxolitinib [INN]; INCB018424 (Ruxolitinib); Ruxolitinib [USAN:INN]; UNII-82S8X8XX8H; Ruxolitinib, S-; INC 424; (ssR)-ss-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; (ssR)-ss-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INC 424; INCB 018424; Ruxolitinib; RXT; Ruxolitinib (Standard); RUXOLITINIB [MI]; Ruxolitinib (USAN/INN); INCB18424,Ruxolitinib; 1092939-15-5; RUXOLITINIB [USAN]; RUXOLITINIB [VANDF]; RUXOLITINIB [WHO-DD]; SCHEMBL171319; GTPL5688; orb1307364; orb3141307; CHEMBL1789941; SCHEMBL16546708; SCHEMBL29349794; HSDB 8259; HFNKQEVNSGCOJV-OAHLLOKOSA-N; GLXC-90091; HMS6018A14; EX-A1670; BDBM50355501; EBC-17053; HY-50856R; NSC763371; NSC800874; INCB018424(R)-RUXOLITINIB; AKOS016842401; CCG-264889; CS-0864; DB08877; FR27771; NSC-763371; NSC-800874; SDCCGSBI-0654261.P002; NCGC00244253-01; NCGC00244253-02; NCGC00244253-11; NCGC00244253-12; NCGC00244253-22; NCGC00244253-23; AC-24280; AC-38227; AS-18619; BP-44052; HY-50856; I5210; D09959; AB01565782_02; EN300-18772174; F092499; Q7383611; BRD-K53972329-001-02-1; BRD-K53972329-001-03-9; BRD-K53972329-001-07-0; (?-R)-?-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (|_R)-|_-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (3R)-3-cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile; 3-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(beta-R)-1H-pyrazole-1-propanenitrile; A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(AR)-1H-pyrazole-1-propanenitrile; betaR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; 1H-PYRAZOLE-1-PROPANENITRILE, .BETA.-CYCLOPENTYL-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (.BETA.R)-; S-Sinónimos
Productos que contienen Ruxolitinib
JAKAVI 5 MG COMPRIMIDOSJAKAVI 20 MG COMPRIMIDOSJAKAVI 15 MG COMPRIMIDOSJAKAVI 10 MG COMPRIMIDOSJakavi 15mgJakavi 20 mgJakavi 10mgRuxotab 5Ruxotab 15Ruxotab 10Ruxotab 20Ruxotab 25
Página 1 de 2
Empresas que venden Ruxolitinib
CP
CHENGHUI PHARMACEUTICAL GROUP LTDChina
NE
Novartis Europharm LimitedSpainCT
Công ty TNHH Novartis Việt NamViet NamSH
Shenzhen Haorui Pharmatech Co., Ltd.China
